Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 88-93 , September 2010

The Compelling Need for a Cardiology and Oncology Partnership and the Birth of the International CardiOncology Society

  • Daniel J. Lenihan

      Affiliations

    • Division of CV Medicine, Vanderbilt University, Nashville, TN, USA
    • ,
  • Daniela Cardinale

      Affiliations

    • Cardiology Unit, European Institute of Oncology, University of Milan, Milan, Italy
    • ,
  • Carlo M. Cipolla

      Affiliations

    • Cardiology Unit, European Institute of Oncology, University of Milan, Milan, Italy
    • Corresponding Author InformationAddress reprint requests to Carlo M. Cipolla, MD, Cardiology Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.

References 

  1. Cardinale D. A new frontier: cardio-oncology. Cardiologia. 1996;41:887–891
  2. Driver JA, Djousse L, Logroscino G, et al. Incidence of cardiovascular disease and cancer in advanced age: prospective cohort study. BMJ. 2008;a2467:337
  3. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. J Am Coll Cardiol. 2007;49:1740–1749
  4. Vaklavas C, Lenihan D, Kurzrock R, et al. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?. Oncologist. 2010;15:130–141
  5. Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14–25
  6. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011–2019
  7. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112:2500–2508
  8. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26:5204–5212
  9. Telli ML, Witteles RM, Fisher GA, et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol. 2008;19:1613–1618
  10. van Royen N, Piek JJ, Schaper W, et al. A critical review of clinical arteriogenesis research. J Am Coll Cardiol. 2009;55:17–25
  11. Mathur A, Martin JF. Stem cells and repair of the heart. Lancet. 2004;364:183–192
  12. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215–1221
  13. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25:3859–3865
  14. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820–7826
  15. Gianni L, Herman EH, Lipshultz SE, et al. Anthracycline cardiotoxicity: from bench to bedside. Journal of Clinical Oncology. 2008;26:3777–3784
  16. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077–1084
  17. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. JACC. 2010;55:213–220
  18. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102:596–604
  19. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26:1231–1238
  20. Chandra S, Lenihan DJ, Wei W, et al. Myocardial perfusion imaging and cardiovascular outcomes in a cancer population. Tex Heart Inst J. 2009;36:205–213
  21. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground?. J Clin Oncol. 2008;26:1201–1203
  22. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008;14:14–24
  23. Goldsmith YB, Liu J, Chou J, et al. Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring. Am J Cardiol. 2009;104:990–994

 Statement of Conflict of Interest: see page 92.

PII: S0033-0620(10)00107-6

doi: 10.1016/j.pcad.2010.06.002

Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 88-93 , September 2010

Article Tools